# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Elizabeth Barrett Browning (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI026-SYN
- Date: 2026-10-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clementine Haverford-Asante, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Seven-month review after an exacerbation: lungs, opioid therapy, mood, safety, weight, and vaccines. **S**

## History of present illness

Ms. Barrett Browning returns seven months after diagnosis and ten weeks after an exacerbation of bronchiectasis, treated at home with amoxicillin for 14 days; the culture from that visit grew Haemophilus influenzae sensitive to amoxicillin, and she was back to her usual sputum within two weeks. She has had no blood since. She finished her sixteen grief sessions in July and had one booster session last month. She has stayed at morphine solution 4 mL twice daily since June, by her choice through the summer and the chest infection, and now asks for the next small step. She is writing every day and has gained weight. **S**

| Element | Detail |
|---|---|
| Exacerbation | One in August, treated at home; recovered in two weeks |
| Opioid | 8 mg twice daily since June; asks for the next step |
| Grief therapy | Sixteen sessions completed and one booster |
| Weight | 44.2 kg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy good |
| Respiratory | Positive | Morning cough with about a tablespoon of sputum; no blood |
| Gastrointestinal | Negative | Appetite good; stools regular |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose, repeat in 2 to 3 minutes in the other nostril if no response; call 911 **S**
- Cholecalciferol (vitamin D3) 1000 unit (25 mcg) oral tablet, two tablets (2000 units) by mouth daily **S**
- Morphine sulfate 2 mg/mL oral solution, 3.5 mL (7 mg) by mouth twice daily, morning and bedtime (14 mg a day) **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/68 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 44.2 kg; BMI 17.9 kg/m². All vital signs are synthetic.

C-reactive protein: 3.2 mg/L; White cell count: 7.4 10*3/uL; PHQ-9: 5. All results are synthetic.

## Change since baseline

- C-reactive protein: 8.4 mg/L (high) at baseline, 3.2 mg/L at this visit **S**
- White cell count: 8.6 10*3/uL at baseline, 7.4 10*3/uL at this visit **S**
- PHQ-9: 12 at baseline, 5 at this visit **S**

## Immunizations given today

- Hepatitis B vaccine (HepB-CpG), dose 2 of 2 **S**
- Influenza vaccine, inactivated, this season **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 44.2 kg, BMI 17.9 |
| Respiratory | A few crackles at the left base; no wheeze |
| Neurological | Not drowsy; pupils normal size |
| Psychiatric | Warm and engaged; no suicidal ideation |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Bronchiectasis** (J47.9). Back to baseline after one exacerbation in seven months; CRP 3.2 mg/L and white count 7.4. The sputum culture sent last week grew normal flora only. With fewer than three exacerbations a year, long-term macrolide is not needed. **S**
   - Continue airway clearance twice daily.
   - Influenza vaccine today; COVID-19 vaccine at her pharmacy this month.
   - Spirometry, Bronchiectasis Severity Index and mycobacterial culture at one year.
2. **Exacerbation of bronchiectasis, resolved** (J47.1). Fully recovered. **S**
   - Keep the exacerbation plan and rescue antibiotic at home.
3. **Long-term opioid therapy: third step** (Z79.891). Down from 20 to 16 mg a day over seven months with no troublesome withdrawal and better sleep and cough; still no opioid use disorder. She chooses a third small step. She may decide to stay at any dose that suits her. **S**
   - Morphine solution 3.5 mL (7 mg) twice daily from today.
   - Prescription monitoring program checked.
   - Urine drug test at one year.
4. **Prolonged grief disorder, improving** (F43.81). PHQ-9 5 from 12 at intake: a response, close to remission. No suicidal ideation. **S**
   - Booster grief sessions as she wishes.
   - PHQ-9 at the next review; safety plan kept.
5. **Underweight, improving** (R63.6). 44.2 kg from 41.5 kg; BMI 17.9. **S**
   - Continue small frequent meals and the supplement drink.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Sputum bacterial culture | At each review and at every exacerbation, before antibiotics | Completed today | Normal flora only; the August exacerbation sample grew Haemophilus influenzae sensitive to amoxicillin |
| Laboratory | C-reactive protein and white cell count | After an exacerbation | Completed today | CRP 3.2 mg/L; white count 7.4 |
| Self-management | Airway clearance technique and exercise | Every visit | Completed today | Twice daily, four times a day during the exacerbation |
| Self-management | Exacerbations: number in the past year, written plan, and rescue antibiotic | Every visit | Completed today | One in seven months, treated at home; plan renewed |
| Self-management | Hemoptysis: amount, and when to seek emergency care | Every visit | Completed today | None since the exacerbation |
| Self-management | Influenza and pneumococcal vaccines | Influenza yearly; pneumococcal once | Completed today | Influenza vaccine today; PCV20 in July |
| Imaging | Spirometry and Bronchiectasis Severity Index | At diagnosis, then yearly | Due | At one year |
| Laboratory | Mycobacterial culture including nontuberculous mycobacteria | At diagnosis (final at six to eight weeks), then yearly and with unexplained decline | Due | At one year |
| Medication safety | Opioid benefits and harms: function, sleep, cough, sedation, breathing, constipation, and her goals | Every visit, and at least every three months | Completed today | No sedation; sleep and cough better; third step chosen |
| Medication safety | Dose reduction at her request: withdrawal symptoms and sleep | Four weeks after each step | Completed today | Second step tolerated without symptoms |
| Medication safety | Prescription drug monitoring program check | With every prescription, and at least every three months | Completed today | One prescriber, one pharmacy |
| Medication safety | Naloxone at home, and no benzodiazepines or other sedatives | Every visit | Completed today | Naloxone in date; no sedatives |
| Survey | PHQ-9 | At least monthly during active treatment (CMID) | Deferred | Missed: no PHQ-9 was recorded between the June visit and today, although the protocol calls for one at least monthly during active treatment. No harm judging by the PHQ-2 of 1 at the July preventive visit, the stable mood at the August sick visit, and today's PHQ-9 of 5. Corrective action: the psychologist's session scores are now entered in the chart, and a monthly PHQ-9 is sent through the patient portal |
| Examination | Suicide risk review and safety plan | Every visit | Completed today | No suicidal ideation; plan kept |
| Self-management | Grief therapy attendance and response | Weekly for sixteen sessions, then boosters | Completed today | Sixteen sessions completed and one booster |
| Examination | Weight and BMI | Every visit | Completed today | 44.2 kg, BMI 17.9 |
| Self-management | Hepatitis B vaccine | Two doses at least four weeks apart | Completed today | Dose 2 given today; series complete |

## Goal progress

- Tuberculosis excluded and a diagnosis for the cough within two weeks. Outcome by 2026-03-23: Smears, NAAT and IGRA negative within a week; bronchiectasis diagnosed by CT at one week. **S**
- Airway clearance twice daily, with less sputum and no blood in it, by three months. Outcome by 2026-06-15: Airway clearance twice daily; sputum down from about four to one tablespoon a day; no blood since the first month. **S**
- Safe opioid therapy: naloxone at home, no overdose or sedation, and any dose change only by her choice. Outcome by 2026-10-19: Naloxone at home; no sedation; she chose to reduce from 20 to 14 mg a day over seven months without troublesome withdrawal. **S**
- Response of grief and depressive symptoms (PHQ-9 down by at least half) by six months. Outcome by 2026-10-19: PHQ-9 5 from 12 after sixteen sessions of grief therapy; she can speak of her brother. **S**
- Weight up toward a BMI of 18.5 (45.6 kg) by seven months. Outcome by 2026-10-19: 44.2 kg from 41.5 kg (BMI 17.9); still gaining. **S**
- Vitamin D above 30 ng/mL by twelve weeks. Outcome by 2026-06-15: 34 ng/mL. **S**

## Medication changes

- Started: Morphine sulfate 2 mg/mL oral solution, 3.5 mL (7 mg) by mouth twice daily, morning and bedtime (14 mg a day) **S**

## Guideline basis

- British Thoracic Society Guideline for Bronchiectasis in Adults (2019), British Thoracic Society (Thorax 2019;74 Suppl 1:1-69)
- European Respiratory Society guidelines for the management of adult bronchiectasis (2017), European Respiratory Society (Eur Respir J 2017;50(3):1700629)
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline (2020), ATS, ERS, ESCMID and IDSA (Clin Infect Dis 2020;71(4):e1-e36)
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recomm Rep 2022;71(3):1-95)
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR): opioid use disorder and prolonged grief disorder criteria (2022), American Psychiatric Association
- Shear MK, et al. Optimizing Treatment of Complicated Grief: A Randomized Clinical Trial (2016), JAMA Psychiatry 2016;73(7):685-694
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression and osteoporosis monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Review in three months with the PHQ-9 and the opioid plan; spirometry, Bronchiectasis Severity Index, sputum and mycobacterial cultures and a urine drug test at one year; pulmonology review if exacerbations reach three a year or blood returns. **S**

